CAESAREA, Israel, June 8, 2015 /PRNewswire/ -- LabStyle Innovations Corp. (DRIO), developer of the Dario Diabetes Management Solution, presented a Late Breaking Poster titled, “Performance of Dario Blood Glucose Monitoring System Evaluated in a Clinical Study in Compliance with the New ISO 15197:2013 Standard,” at the ADA’s 75th Anniversary Scientific Sessions.
Dr. Paul Rosman, a member of the LabStyle Innovations Scientific Advisory Board, delivered the presentation at the ADA’s Scientific Session that brings together over 14,000 participants from 124 countries. The poster revealed the results of a 368 patient Diabetes Type 1 and Type 2 study that was performed in the United States.
Results of the study, which was carried out in Ohio, showed that the Dario Blood Glucose Monitoring System meets the acceptance criteria of new more stringent ISO 15197:2013. 97.8% of the Dario glucose results fall within + 0.83 mmol/L (15 mg/dL) at glucose concentrations < 5.5 mmol/L (< 100 mg/dL) and 96.49% of the Dario glucose results fall within + 15% at glucose concentrations >5.5 mmol/L (>100 mg/dL).
In addition the study demonstrated that usage of the Dario Diabetes Management Solution is simple and intuitive and that the instructional material provided with the device is sufficient to allow a layperson to easily use it.
“I am very excited to have this opportunity to present the very positive results of the performance study that was done at the prestigious ADA scientific session. Dario has been proven to deliver superb accuracy and excellent patient usability which is in line with the experiences patients are having when using Dario to manage their diabetes in their daily lives.” stated Dr. Rosman.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario Diabetes Management Solution. Dario empowers people with diabetes to take charge of their health with the right tools, insights, and support in their pocket. With access to both real-time and historical blood glucose data, Dario is designed to spot patterns, recommend the right treatments and support behavior change efforts.
Dario is a platform that combines an all-in-one, blood glucose meter, smart phone application (iOS & Android), website application and treatment tools to support more proactive and better informed decisions by patients, doctors and healthcare systems. The stylish and compact self-monitoring system combines a lancet to obtain a blood sample, a proprietary disposable test strip cartridge and a smartphone-driven glucose meter. LabStyle Innovations is led by an experienced management team with vast software, medical device and technology experience and is guided by a world class board of directors and scientific advisory board. For more information: www.myDario.com and http://myDario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Contacts:
Press and Investor Relations
Brenda Zeitlin
LabStyle Innovations
1 800 896 9062
Brenda@mydario.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/labstyle-innovations-late-breaking-poster-presented-at-american-diabetes-association-75th-scientific-session-300095332.html
SOURCE LabStyle Innovations Corp.
Help employers find you! Check out all the jobs and post your resume.
